market depends on pharma commercialization, medical affairs and regulatory outsourcing with an estimation at over USD 40bn by 2033, yet Indegene's FY26 revenue represents well under 0.2% of this opportunity. Rising drug development costs, patent cliffs, and increasing outsourcing...